PRESS RELEASE published on 03/04/2026 at 22:30, 6 months 8 days ago DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies to participate in upcoming investor conferences to present its late-stage biopharmaceutical developments for food allergies. Company uses proprietary VIASKIN patch technology for treatment Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/03/2026 at 22:35, 6 months 9 days ago DBV Technologies: Update on voting rights and shares Euronext Paris Share Capital Voting Rights Financial Regulations DBV Technologies
BRIEF published on 03/03/2026 at 22:35, 6 months 9 days ago DBV Technologies: February 2026 Voting Rights and Shares Update Voting Rights Shares DBV Technologies NYSE Euronext Paris February 2026
PRESS RELEASE published on 03/03/2026 at 22:30, 6 months 9 days ago Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 Important update on total voting rights and shares as of February 28, 2026 for NYSE Euronext Paris. Total gross voting rights: 278,352,082 Shares Total Voting Rights Regulations NYSE Euronext Paris February 28 2026
BRIEF published on 03/02/2026 at 15:53, 6 months 11 days ago JP Morgan's investment in DBV Technologies reaches new thresholds Crossing Thresholds Equity Swaps Shares And Voting Rights DBV Technologies JP Morgan
BRIEF published on 02/28/2026 at 20:30, 6 months 13 days ago DBV Technologies Unveils Promising Phase 3 VITESSE Study Results at AAAAI 2026 DBV Technologies Phase 3 Results Viaskin Peanut Patch Peanut Allergy Treatment VITESSE Study
BRIEF published on 02/28/2026 at 20:30, 6 months 13 days ago DBV Technologies reveals promising new results for VIASKIN Peanut Clinical Study Immunotherapy DBV Technologies Food Allergies Viaskin Peanut
PRESS RELEASE published on 02/28/2026 at 20:25, 6 months 13 days ago DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting DBV Technologies presents successful Phase 3 VITESSE study data at AAAAI Annual Meeting, highlighting VIASKIN Peanut Patch efficacy in treating peanut-allergic children DBV Technologies Food Allergies Viaskin Peanut Patch Phase 3 VITESSE Study AAAAI Annual Meeting
BRIEF published on 02/09/2026 at 22:35, 7 months 3 days ago DBV Technologies at the Emerging Outlook: Biotech Summit conference Immunotherapy DBV Technologies Viaskin Food Allergies Biotech Summit
BRIEF published on 02/09/2026 at 22:35, 7 months 3 days ago DBV Technologies to Join Guggenheim Biotech Summit Biopharmaceutical DBV Technologies Food Allergies VIASKIN® Patch Guggenheim Securities Summit
Published on 09/12/2026 at 02:35, 1 day 19 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 22 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 2 days ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 4 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 day 4 hours ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 14 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 23 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 23 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 days 2 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 14 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 3 days 2 hours ago Availability of the 2026 Interim Financial Report
